Loading…

Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study

The purpose of the present study was to investigate microcirculatory blood flow in patients with septic shock treated with levosimendan as compared to an active comparator drug (i.e. dobutamine). The primary end point was a difference of ≥ 20% in the microvascular flow index of small vessels (MFIs)...

Full description

Saved in:
Bibliographic Details
Published in:Critical care (London, England) England), 2010-01, Vol.14 (6), p.R232-R232, Article R232
Main Authors: Morelli, Andrea, Donati, Abele, Ertmer, Christian, Rehberg, Sebastian, Lange, Matthias, Orecchioni, Alessandra, Cecchini, Valeria, Landoni, Giovanni, Pelaia, Paolo, Pietropaoli, Paolo, Van Aken, Hugo, Teboul, Jean-Louis, Ince, Can, Westphal, Martin
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b415t-3977ba36f40286335d5d86c10fa198179cfcbee48468e4e652883b8ad0a340c3
cites cdi_FETCH-LOGICAL-b415t-3977ba36f40286335d5d86c10fa198179cfcbee48468e4e652883b8ad0a340c3
container_end_page R232
container_issue 6
container_start_page R232
container_title Critical care (London, England)
container_volume 14
creator Morelli, Andrea
Donati, Abele
Ertmer, Christian
Rehberg, Sebastian
Lange, Matthias
Orecchioni, Alessandra
Cecchini, Valeria
Landoni, Giovanni
Pelaia, Paolo
Pietropaoli, Paolo
Van Aken, Hugo
Teboul, Jean-Louis
Ince, Can
Westphal, Martin
description The purpose of the present study was to investigate microcirculatory blood flow in patients with septic shock treated with levosimendan as compared to an active comparator drug (i.e. dobutamine). The primary end point was a difference of ≥ 20% in the microvascular flow index of small vessels (MFIs) among groups. The study was designed as a prospective, randomized, double-blind clinical trial and performed in a multidisciplinary intensive care unit. After achieving normovolemia and a mean arterial pressure of at least 65 mmHg, 40 septic shock patients were randomized to receive either levosimendan 0.2 μg·kg(-1)·min(-1) (n = 20) or an active comparator (dobutamine 5 μg·kg(-1)·min(-1); control; n = 20) for 24 hours. Sublingual microcirculatory blood flow of small and medium vessels was assessed by sidestream dark-field imaging. Microcirculatory variables and data from right heart catheterization were obtained at baseline and 24 hours after randomization. Baseline and demographic data were compared by means of Mann-Whitney rank sum test or chi-square test, as appropriate. Microvascular and hemodynamic variables were analyzed using the Mann-Whitney rank sum test. Microcirculatory flow indices of small and medium vessels increased over time and were significantly higher in the levosimendan group as compared to the control group (24 hrs: MFIm 3.0 (3.0; 3.0) vs. 2.9 (2.8; 3.0); P = .02; MFIs 2.9 (2.9; 3.0) vs. 2.7 (2.3; 2.8); P < .001). The relative increase of perfused vessel density vs. baseline was significantly higher in the levosimendan group than in the control group (dMFIm 10 (3; 23)% vs. 0 (-1; 9)%; P = .007; dMFIs 47 (26; 83)% vs. 10 (-3; 27); P < .001). In addition, the heterogeneity index decreased only in the levosimendan group (dHI -93 (-100; -84)% vs. 0 (-78; 57)%; P < .001). There was no statistically significant correlation between systemic and microcirculatory flow variables within each group (each P > .05). Compared to a standard dose of 5 μg·kg(-1)·min(-1) of dobutamine, levosimendan at 0.2 μg·kg(-1)·min(-1) improved sublingual microcirculatory blood flow in patients with septic shock, as reflected by changes in microcirculatory flow indices of small and medium vessels. NCT00800306.
doi_str_mv 10.1186/cc9387
format article
fullrecord <record><control><sourceid>biomedcentral_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3219978</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_biomedcentral_com_cc9387</sourcerecordid><originalsourceid>FETCH-LOGICAL-b415t-3977ba36f40286335d5d86c10fa198179cfcbee48468e4e652883b8ad0a340c3</originalsourceid><addsrcrecordid>eNp1UT1PwzAUtBCIQoGfgDyxBew4cRwGJFTxJVVi6cAWObbTGhI7sp2i8usxChQ6ML3Te-9OpzsAzjC6xJjRKyFKwoo9cIQzShOKypf9iAnNEpaTfAKOvX9FCBeMkkMwSSMnLRg5Av1cra3XnTKSG9hYB53ygxc68KDNEoaVgp0WzgrtxNDGpTVQG9hHpEzw8F2HFfSqD1pAv7Li7Rpy6LiRttMfSkJhTXC2bSP0YZCbE3DQ8Nar0-85BYv7u8XsMZk_PzzNbudJneE8JKQsipoT2mQojZ5JLnPJqMCo4bhkuChFI2qlMpZRpjJF85QxUjMuEScZEmQKbkbZfqg7JUX06nhb9U533G0qy3W1ezF6VS3tuiIpLssYzRSUo0Ct7T8Cuxdhu2psIXIvRm7MzXunmi0No-qrrt_H878ut28__ZBPK4mVuA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study</title><source>PubMed (Medline)</source><creator>Morelli, Andrea ; Donati, Abele ; Ertmer, Christian ; Rehberg, Sebastian ; Lange, Matthias ; Orecchioni, Alessandra ; Cecchini, Valeria ; Landoni, Giovanni ; Pelaia, Paolo ; Pietropaoli, Paolo ; Van Aken, Hugo ; Teboul, Jean-Louis ; Ince, Can ; Westphal, Martin</creator><creatorcontrib>Morelli, Andrea ; Donati, Abele ; Ertmer, Christian ; Rehberg, Sebastian ; Lange, Matthias ; Orecchioni, Alessandra ; Cecchini, Valeria ; Landoni, Giovanni ; Pelaia, Paolo ; Pietropaoli, Paolo ; Van Aken, Hugo ; Teboul, Jean-Louis ; Ince, Can ; Westphal, Martin</creatorcontrib><description>The purpose of the present study was to investigate microcirculatory blood flow in patients with septic shock treated with levosimendan as compared to an active comparator drug (i.e. dobutamine). The primary end point was a difference of ≥ 20% in the microvascular flow index of small vessels (MFIs) among groups. The study was designed as a prospective, randomized, double-blind clinical trial and performed in a multidisciplinary intensive care unit. After achieving normovolemia and a mean arterial pressure of at least 65 mmHg, 40 septic shock patients were randomized to receive either levosimendan 0.2 μg·kg(-1)·min(-1) (n = 20) or an active comparator (dobutamine 5 μg·kg(-1)·min(-1); control; n = 20) for 24 hours. Sublingual microcirculatory blood flow of small and medium vessels was assessed by sidestream dark-field imaging. Microcirculatory variables and data from right heart catheterization were obtained at baseline and 24 hours after randomization. Baseline and demographic data were compared by means of Mann-Whitney rank sum test or chi-square test, as appropriate. Microvascular and hemodynamic variables were analyzed using the Mann-Whitney rank sum test. Microcirculatory flow indices of small and medium vessels increased over time and were significantly higher in the levosimendan group as compared to the control group (24 hrs: MFIm 3.0 (3.0; 3.0) vs. 2.9 (2.8; 3.0); P = .02; MFIs 2.9 (2.9; 3.0) vs. 2.7 (2.3; 2.8); P &lt; .001). The relative increase of perfused vessel density vs. baseline was significantly higher in the levosimendan group than in the control group (dMFIm 10 (3; 23)% vs. 0 (-1; 9)%; P = .007; dMFIs 47 (26; 83)% vs. 10 (-3; 27); P &lt; .001). In addition, the heterogeneity index decreased only in the levosimendan group (dHI -93 (-100; -84)% vs. 0 (-78; 57)%; P &lt; .001). There was no statistically significant correlation between systemic and microcirculatory flow variables within each group (each P &gt; .05). Compared to a standard dose of 5 μg·kg(-1)·min(-1) of dobutamine, levosimendan at 0.2 μg·kg(-1)·min(-1) improved sublingual microcirculatory blood flow in patients with septic shock, as reflected by changes in microcirculatory flow indices of small and medium vessels. NCT00800306.</description><identifier>ISSN: 1364-8535</identifier><identifier>EISSN: 1466-609X</identifier><identifier>EISSN: 1364-8535</identifier><identifier>DOI: 10.1186/cc9387</identifier><identifier>PMID: 21182783</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Aged ; Double-Blind Method ; Female ; Humans ; Hydrazones - therapeutic use ; Male ; Microcirculation - drug effects ; Middle Aged ; Mouth Floor - blood supply ; Prospective Studies ; Pyridazines - therapeutic use ; Resuscitation - methods ; Shock, Septic - drug therapy ; Shock, Septic - physiopathology</subject><ispartof>Critical care (London, England), 2010-01, Vol.14 (6), p.R232-R232, Article R232</ispartof><rights>Copyright ©2010 Morelli et al.; licensee BioMed Central Ltd. 2010 Morelli et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b415t-3977ba36f40286335d5d86c10fa198179cfcbee48468e4e652883b8ad0a340c3</citedby><cites>FETCH-LOGICAL-b415t-3977ba36f40286335d5d86c10fa198179cfcbee48468e4e652883b8ad0a340c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219978/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219978/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21182783$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morelli, Andrea</creatorcontrib><creatorcontrib>Donati, Abele</creatorcontrib><creatorcontrib>Ertmer, Christian</creatorcontrib><creatorcontrib>Rehberg, Sebastian</creatorcontrib><creatorcontrib>Lange, Matthias</creatorcontrib><creatorcontrib>Orecchioni, Alessandra</creatorcontrib><creatorcontrib>Cecchini, Valeria</creatorcontrib><creatorcontrib>Landoni, Giovanni</creatorcontrib><creatorcontrib>Pelaia, Paolo</creatorcontrib><creatorcontrib>Pietropaoli, Paolo</creatorcontrib><creatorcontrib>Van Aken, Hugo</creatorcontrib><creatorcontrib>Teboul, Jean-Louis</creatorcontrib><creatorcontrib>Ince, Can</creatorcontrib><creatorcontrib>Westphal, Martin</creatorcontrib><title>Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study</title><title>Critical care (London, England)</title><addtitle>Crit Care</addtitle><description>The purpose of the present study was to investigate microcirculatory blood flow in patients with septic shock treated with levosimendan as compared to an active comparator drug (i.e. dobutamine). The primary end point was a difference of ≥ 20% in the microvascular flow index of small vessels (MFIs) among groups. The study was designed as a prospective, randomized, double-blind clinical trial and performed in a multidisciplinary intensive care unit. After achieving normovolemia and a mean arterial pressure of at least 65 mmHg, 40 septic shock patients were randomized to receive either levosimendan 0.2 μg·kg(-1)·min(-1) (n = 20) or an active comparator (dobutamine 5 μg·kg(-1)·min(-1); control; n = 20) for 24 hours. Sublingual microcirculatory blood flow of small and medium vessels was assessed by sidestream dark-field imaging. Microcirculatory variables and data from right heart catheterization were obtained at baseline and 24 hours after randomization. Baseline and demographic data were compared by means of Mann-Whitney rank sum test or chi-square test, as appropriate. Microvascular and hemodynamic variables were analyzed using the Mann-Whitney rank sum test. Microcirculatory flow indices of small and medium vessels increased over time and were significantly higher in the levosimendan group as compared to the control group (24 hrs: MFIm 3.0 (3.0; 3.0) vs. 2.9 (2.8; 3.0); P = .02; MFIs 2.9 (2.9; 3.0) vs. 2.7 (2.3; 2.8); P &lt; .001). The relative increase of perfused vessel density vs. baseline was significantly higher in the levosimendan group than in the control group (dMFIm 10 (3; 23)% vs. 0 (-1; 9)%; P = .007; dMFIs 47 (26; 83)% vs. 10 (-3; 27); P &lt; .001). In addition, the heterogeneity index decreased only in the levosimendan group (dHI -93 (-100; -84)% vs. 0 (-78; 57)%; P &lt; .001). There was no statistically significant correlation between systemic and microcirculatory flow variables within each group (each P &gt; .05). Compared to a standard dose of 5 μg·kg(-1)·min(-1) of dobutamine, levosimendan at 0.2 μg·kg(-1)·min(-1) improved sublingual microcirculatory blood flow in patients with septic shock, as reflected by changes in microcirculatory flow indices of small and medium vessels. NCT00800306.</description><subject>Aged</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrazones - therapeutic use</subject><subject>Male</subject><subject>Microcirculation - drug effects</subject><subject>Middle Aged</subject><subject>Mouth Floor - blood supply</subject><subject>Prospective Studies</subject><subject>Pyridazines - therapeutic use</subject><subject>Resuscitation - methods</subject><subject>Shock, Septic - drug therapy</subject><subject>Shock, Septic - physiopathology</subject><issn>1364-8535</issn><issn>1466-609X</issn><issn>1364-8535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNp1UT1PwzAUtBCIQoGfgDyxBew4cRwGJFTxJVVi6cAWObbTGhI7sp2i8usxChQ6ML3Te-9OpzsAzjC6xJjRKyFKwoo9cIQzShOKypf9iAnNEpaTfAKOvX9FCBeMkkMwSSMnLRg5Av1cra3XnTKSG9hYB53ygxc68KDNEoaVgp0WzgrtxNDGpTVQG9hHpEzw8F2HFfSqD1pAv7Li7Rpy6LiRttMfSkJhTXC2bSP0YZCbE3DQ8Nar0-85BYv7u8XsMZk_PzzNbudJneE8JKQsipoT2mQojZ5JLnPJqMCo4bhkuChFI2qlMpZRpjJF85QxUjMuEScZEmQKbkbZfqg7JUX06nhb9U533G0qy3W1ezF6VS3tuiIpLssYzRSUo0Ct7T8Cuxdhu2psIXIvRm7MzXunmi0No-qrrt_H878ut28__ZBPK4mVuA</recordid><startdate>20100101</startdate><enddate>20100101</enddate><creator>Morelli, Andrea</creator><creator>Donati, Abele</creator><creator>Ertmer, Christian</creator><creator>Rehberg, Sebastian</creator><creator>Lange, Matthias</creator><creator>Orecchioni, Alessandra</creator><creator>Cecchini, Valeria</creator><creator>Landoni, Giovanni</creator><creator>Pelaia, Paolo</creator><creator>Pietropaoli, Paolo</creator><creator>Van Aken, Hugo</creator><creator>Teboul, Jean-Louis</creator><creator>Ince, Can</creator><creator>Westphal, Martin</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20100101</creationdate><title>Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study</title><author>Morelli, Andrea ; Donati, Abele ; Ertmer, Christian ; Rehberg, Sebastian ; Lange, Matthias ; Orecchioni, Alessandra ; Cecchini, Valeria ; Landoni, Giovanni ; Pelaia, Paolo ; Pietropaoli, Paolo ; Van Aken, Hugo ; Teboul, Jean-Louis ; Ince, Can ; Westphal, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b415t-3977ba36f40286335d5d86c10fa198179cfcbee48468e4e652883b8ad0a340c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrazones - therapeutic use</topic><topic>Male</topic><topic>Microcirculation - drug effects</topic><topic>Middle Aged</topic><topic>Mouth Floor - blood supply</topic><topic>Prospective Studies</topic><topic>Pyridazines - therapeutic use</topic><topic>Resuscitation - methods</topic><topic>Shock, Septic - drug therapy</topic><topic>Shock, Septic - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morelli, Andrea</creatorcontrib><creatorcontrib>Donati, Abele</creatorcontrib><creatorcontrib>Ertmer, Christian</creatorcontrib><creatorcontrib>Rehberg, Sebastian</creatorcontrib><creatorcontrib>Lange, Matthias</creatorcontrib><creatorcontrib>Orecchioni, Alessandra</creatorcontrib><creatorcontrib>Cecchini, Valeria</creatorcontrib><creatorcontrib>Landoni, Giovanni</creatorcontrib><creatorcontrib>Pelaia, Paolo</creatorcontrib><creatorcontrib>Pietropaoli, Paolo</creatorcontrib><creatorcontrib>Van Aken, Hugo</creatorcontrib><creatorcontrib>Teboul, Jean-Louis</creatorcontrib><creatorcontrib>Ince, Can</creatorcontrib><creatorcontrib>Westphal, Martin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Critical care (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morelli, Andrea</au><au>Donati, Abele</au><au>Ertmer, Christian</au><au>Rehberg, Sebastian</au><au>Lange, Matthias</au><au>Orecchioni, Alessandra</au><au>Cecchini, Valeria</au><au>Landoni, Giovanni</au><au>Pelaia, Paolo</au><au>Pietropaoli, Paolo</au><au>Van Aken, Hugo</au><au>Teboul, Jean-Louis</au><au>Ince, Can</au><au>Westphal, Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study</atitle><jtitle>Critical care (London, England)</jtitle><addtitle>Crit Care</addtitle><date>2010-01-01</date><risdate>2010</risdate><volume>14</volume><issue>6</issue><spage>R232</spage><epage>R232</epage><pages>R232-R232</pages><artnum>R232</artnum><issn>1364-8535</issn><eissn>1466-609X</eissn><eissn>1364-8535</eissn><abstract>The purpose of the present study was to investigate microcirculatory blood flow in patients with septic shock treated with levosimendan as compared to an active comparator drug (i.e. dobutamine). The primary end point was a difference of ≥ 20% in the microvascular flow index of small vessels (MFIs) among groups. The study was designed as a prospective, randomized, double-blind clinical trial and performed in a multidisciplinary intensive care unit. After achieving normovolemia and a mean arterial pressure of at least 65 mmHg, 40 septic shock patients were randomized to receive either levosimendan 0.2 μg·kg(-1)·min(-1) (n = 20) or an active comparator (dobutamine 5 μg·kg(-1)·min(-1); control; n = 20) for 24 hours. Sublingual microcirculatory blood flow of small and medium vessels was assessed by sidestream dark-field imaging. Microcirculatory variables and data from right heart catheterization were obtained at baseline and 24 hours after randomization. Baseline and demographic data were compared by means of Mann-Whitney rank sum test or chi-square test, as appropriate. Microvascular and hemodynamic variables were analyzed using the Mann-Whitney rank sum test. Microcirculatory flow indices of small and medium vessels increased over time and were significantly higher in the levosimendan group as compared to the control group (24 hrs: MFIm 3.0 (3.0; 3.0) vs. 2.9 (2.8; 3.0); P = .02; MFIs 2.9 (2.9; 3.0) vs. 2.7 (2.3; 2.8); P &lt; .001). The relative increase of perfused vessel density vs. baseline was significantly higher in the levosimendan group than in the control group (dMFIm 10 (3; 23)% vs. 0 (-1; 9)%; P = .007; dMFIs 47 (26; 83)% vs. 10 (-3; 27); P &lt; .001). In addition, the heterogeneity index decreased only in the levosimendan group (dHI -93 (-100; -84)% vs. 0 (-78; 57)%; P &lt; .001). There was no statistically significant correlation between systemic and microcirculatory flow variables within each group (each P &gt; .05). Compared to a standard dose of 5 μg·kg(-1)·min(-1) of dobutamine, levosimendan at 0.2 μg·kg(-1)·min(-1) improved sublingual microcirculatory blood flow in patients with septic shock, as reflected by changes in microcirculatory flow indices of small and medium vessels. NCT00800306.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>21182783</pmid><doi>10.1186/cc9387</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1364-8535
ispartof Critical care (London, England), 2010-01, Vol.14 (6), p.R232-R232, Article R232
issn 1364-8535
1466-609X
1364-8535
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3219978
source PubMed (Medline)
subjects Aged
Double-Blind Method
Female
Humans
Hydrazones - therapeutic use
Male
Microcirculation - drug effects
Middle Aged
Mouth Floor - blood supply
Prospective Studies
Pyridazines - therapeutic use
Resuscitation - methods
Shock, Septic - drug therapy
Shock, Septic - physiopathology
title Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T02%3A07%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-biomedcentral_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Levosimendan%20for%20resuscitating%20the%20microcirculation%20in%20patients%20with%20septic%20shock:%20a%20randomized%20controlled%20study&rft.jtitle=Critical%20care%20(London,%20England)&rft.au=Morelli,%20Andrea&rft.date=2010-01-01&rft.volume=14&rft.issue=6&rft.spage=R232&rft.epage=R232&rft.pages=R232-R232&rft.artnum=R232&rft.issn=1364-8535&rft.eissn=1466-609X&rft_id=info:doi/10.1186/cc9387&rft_dat=%3Cbiomedcentral_pubme%3Eoai_biomedcentral_com_cc9387%3C/biomedcentral_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b415t-3977ba36f40286335d5d86c10fa198179cfcbee48468e4e652883b8ad0a340c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/21182783&rfr_iscdi=true